Profound Medical Corp. (PROF)
NASDAQ: PROF · Real-Time Price · USD
7.84
+0.32 (4.26%)
Sep 19, 2024, 4:00 PM EDT - Market closed
Profound Medical Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Profound Medical stock have an average target of 11.4, with a low estimate of 10.8 and a high estimate of 12. The average target predicts an increase of 45.41% from the current stock price of 7.84.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jul 16, 2024.
Analyst Ratings
The average analyst rating for PROF stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 1 | 1 | 0 |
| Hold | 2 | 2 | 2 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Hold → Strong Buy Upgrades $9 → $12 | Hold → Strong Buy | Upgrades | $9 → $12 | +53.06% | Jul 16, 2024 |
| Alliance Global Partners | Alliance Global Partners | Strong Buy Maintains $13 → $11 | Strong Buy | Maintains | $13 → $11 | +37.76% | Mar 11, 2024 |
| Stifel | Stifel | Hold Maintains $11 → $9 | Hold | Maintains | $11 → $9 | +14.80% | Mar 8, 2024 |
| Alliance Global Partners | Alliance Global Partners | Strong Buy Maintains $14 → $13 | Strong Buy | Maintains | $14 → $13 | +62.63% | Jan 4, 2024 |
| Stifel | Stifel | Hold Initiates $11 | Hold | Initiates | $11 | +40.31% | Nov 28, 2023 |
Financial Forecast
Revenue This Year
11.29M
from 7.20M
Increased by 56.87%
Revenue Next Year
29.58M
from 11.29M
Increased by 161.94%
EPS This Year
-1.14
from -1.35
EPS Next Year
-0.92
from -1.14
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 12.0M | 49.8M | 87.5M | ||
| Avg | 11.3M | 29.6M | 50.0M | ||
| Low | 10.7M | 16.5M | 32.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 66.3% | 340.7% | 195.7% | ||
| Avg | 56.9% | 161.9% | 68.9% | ||
| Low | 48.5% | 45.8% | 9.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -1.03 | -0.75 | 0.22 | |
| Avg | -1.14 | -0.92 | -0.49 | |
| Low | -1.17 | -1.25 | -1.24 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.